As of 2024-10-05, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 74.38 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 17.4x | 13.9x |
| Forward P/E multiples | 17.6x - 20.5x | 17.7x |
| Fair Price | (940.64) - (930.09) | (844.63) |
| Upside | -306196.9% - -302763.9% | -274956.4% |
| Date | EV/EBITDA |
| 2024-10-04 | -0.21 |
| 2024-10-03 | -0.21 |
| 2024-10-02 | -0.21 |
| 2024-10-01 | -0.21 |
| 2024-09-30 | -0.21 |
| 2024-09-27 | -0.21 |
| 2024-09-26 | -0.21 |
| 2024-09-25 | -0.21 |
| 2024-09-24 | -0.21 |
| 2024-09-23 | -0.21 |
| 2024-09-20 | -0.21 |
| 2024-09-19 | -0.21 |
| 2024-09-18 | -0.21 |
| 2024-09-17 | -0.21 |
| 2024-09-16 | -0.21 |
| 2024-09-13 | -0.21 |
| 2024-09-12 | -0.21 |
| 2024-09-11 | -0.21 |
| 2024-09-10 | -0.21 |
| 2024-09-09 | -0.21 |
| 2024-09-06 | -0.21 |
| 2024-09-05 | -0.21 |
| 2024-09-04 | -0.21 |
| 2024-09-03 | -0.21 |
| 2024-08-30 | -0.21 |
| 2024-08-29 | -0.21 |
| 2024-08-28 | -0.21 |
| 2024-08-27 | -0.21 |
| 2024-08-26 | -0.21 |
| 2024-08-23 | -0.21 |
| 2024-08-22 | -0.21 |
| 2024-08-21 | -0.21 |
| 2024-08-20 | -0.21 |
| 2024-08-19 | -0.21 |
| 2024-08-16 | -0.21 |
| 2024-08-15 | -0.21 |
| 2024-08-14 | -0.21 |
| 2024-08-13 | -0.21 |
| 2024-08-12 | -0.21 |
| 2024-08-09 | -0.21 |
| 2024-08-08 | -0.21 |
| 2024-08-07 | -0.21 |
| 2024-08-06 | -0.21 |
| 2024-08-05 | -0.21 |
| 2024-08-02 | -0.21 |
| 2024-08-01 | -0.21 |
| 2024-07-31 | -0.21 |
| 2024-07-30 | -0.21 |
| 2024-07-29 | -0.21 |
| 2024-07-26 | -0.21 |